Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1 by Gabellini, C et al.
Telomerase activity, apoptosis and cell cycle progression in ataxia
telangiectasia lymphocytes expressing TCL1
C Gabellini
1, A Antonelli
2, P Petrinelli
2, A Biroccio
1, L Marcucci
2, G Nigro
3, G Russo
4, G Zupi
1 and R Elli*,2
1Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy;
2Cellular Biotechnology and Hematology Department, University ‘La
Sapienza’, Rome, Italy;
3Pediatric Institute, University ‘La Sapienza’, Rome, Italy;
4Istituto Dermopatico dell’ Immacolata, Rome, Italy
Individuals affected by ataxia telangiectasia (AT) have a marked susceptibility to cancer. Ataxia telangiectasia cells, in addition to
defects in cell cycle checkpoints, show dysfunction of apoptosis and of telomeres, which are both thought to have a role in the
progression of malignancy. In 1–5% of patients with AT, clonal expansion of T lymphocytes carrying t(14;14) chromosomal
translocation, deregulating TCL1 gene(s), has been described. While it is known that these cells can progress with time to a frank
leukaemia, the molecular pathway leading to tumorigenesis has not yet been fully investigated. In this study, we compared AT clonal
cells, representing 88% of the entire T lymphocytes (AT94-1) and expressing TCL1 oncogene (ATM
  TCL1
þ), cell cycle progression
to T lymphocytes of AT patients without TCL1 expression (ATM
  TCL1
 ) by analysing their spontaneous apoptosis rate,
spontaneous telomerase activity and telomere instability. We show that in ATM
  TCL1
þ lymphocytes, apoptosis rate and cell cycle
progression are restored back to a rate comparable with that observed in normal lymphocytes while telomere dysfunction is
maintained.
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Ataxia telangiectasia (AT) is an autosomal recessive disease
characterised by progressive cerebellar degeneration, variable
immunodeficiency, genomic instability and susceptibility to
cancer, especially lymphoid malignancies. The product of ATM
gene, which is mutated in individuals affected by AT, belongs to
a well-conserved family of protein kinases. It is involved in the
control of the cell cycle, in the processing of DNA damage and
in the maintenance of genome integrity (caretaker gene) (Shiloh
and Kastan, 2001). In particular, the Atm protein is homologous
to Tel1p, which is essential for telomere maintenance in
Saccharomyces cerevisiae (Greenwell et al, 1995; Pandita, 2002),
and may regulate the structure and the function of telomeres
through a not yet fully understood mechanism; indeed, AT cells
have an accelerated rate of telomere loss and show chromosomal
end-to-end telomeric fusions/associations (tas), in spite of having
normal telomerase activity (Pandita et al, 1995; Metcalfe et al,
1996). Furthermore, Atm might play a role in apoptosis as
suggested by its involvement as a substrate of caspase 3 (Smith
et al, 1999); however, different cell types that lack the ATM
function show apoptotic behaviour not always consistent (Meyn,
1999; Bebb et al, 2001).
Tumours of the lymphoid system are very frequent in AT
patients. Among them T-prolymphocytic leukaemia (T-PLL), a
very rare lymphoid neoplasia in general population, is also quite
often observed in AT patients (Taylor et al, 1996). These T-PLLs
in ATs have been well characterised in the past by several
groups including us, and are quite invariably preceded by a T cell
clonal expansion identifiable cytogenetically to carry a t(14;14)
(q11;q32.1) translocation or an inv(14)(q11;q32.1) inversion or a
t(X;14)(q28;q32.1) translocation. With the time, usually years,
these clonal cells are able to expand until they represent up to
90% of the circulating T lymphocytes and ultimately to evolve into
an overt leukaemia. These chromosomal rearrangements, at
molecular level, bring regulatory elements of the TCRa (located
on14q11) to a new position on 14q32.1 or Xq28 resulting in
activation of usually silent genes in normal mature T cells. These
genes belong to the TCL1 gene family: TCL1 and TCL1b are
located on 14q32.1 and MTCP1 is on Xq28 (Stern et al, 1993;
Virgilio et al, 1994; Pekarsky et al, 1999). Tcl1, Tcl1b and Mtcp1
identify a new family of proteins since they are practically
identical, either by sequence or structure, and are usually absent
in mature normal circulating T cells. The consequences of
TCL1 expression are due to its binding to the serine/threonine
kinase Akt (also called protein kinase B, PKB), by increasing
kinase activity and enhancing Akt nuclear translocation (Laine
et al, 2000; Pekarsky et al, 2000). Furthermore, TCL1 family
gene members have oncogenic ability, as clearly demonstrated by
four different transgenic animal models in which overexpression
of these genes, in either T or B cells, causes T-PLL, B-chronic
lymphocytic leukaemia (B-CLL) or mature B-cell lymphoma
(Gritti et al, 1998; Virgilio et al, 1998; Bichi et al, 2002; Hoyer
et al, 2002).
We previously described a large nonleukaemic clone carrying
the chromosomal tandem translocation t(14;14)(q11;q32) in an Received 19 March 2003; accepted 25 June 2003
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sAT patient (AT94-1), who, at present, has not yet shown any
sign of malignancy. The clonal cells are characterised by the
overexpression of the TCL1 oncogene (Narducci et al, 1995), a
high rate of spontaneous chromosome instability (especially of tas)
(Petrinelli et al, 2001) and hypersensitivity to the topoisomerase II
inhibitor VP16 (Petrinelli et al, 1996). These clonal cells represent
a very useful tool to study the biological consequences of TCL1
overexpression in the context of ATM deficiency since they are not
hampered by ectopic transfection. In this study, we report that in
this AT cell clone, even when VP16-damaged, the apoptosis rate
and the cell cycle progression are restored back to a rate
comparable with that observed in normal lymphocytes while
telomere dysfunction is maintained.
MATERIALS AND METHODS
Lymphocyte cultures
Peripheral blood samples were obtained from the AT94-1 patient,
from six normal controls and from two AT controls (AT95-1 and
AT95-2). AT94-1 and AT95-2 were reported as AT22RM and
AT28RM, respectively, by Gilad et al (1996).
To evaluate the spontaneous rate of tas, chromosome prepara-
tions were performed by standard method, and analysed on G-
banded metaphases by two independent observers.
To evaluate telomerase activity, telomere length, cell cycle
progression and apoptosis, blood was defibrinated and mono-
nuclear cells isolated by centrifugation on a layer of histopaque
1077 (Sigma Diagnostic, Milan, Italy). Purified lymphocytes
(1 10
6ml
 1) were incubated for 72h in RPMI 1640 (Sigma)
supplemented with 10% fetal calf serum, penicillin, streptomycin
and PHA (5mgml
 1). To evaluate the effects of the topoisome-
raseII inhibitor VP16 on cell cycle and apoptosis, VP16 (final
concentration 0.1mgml
 1) was added to purified lymphocyte
cultures 48h before harvesting (Petrinelli et al, 1996).
Telomerase activity and telomere length
Telomerase activity was measured with the PCR-based TRAP
(telomeric repeat amplification protocol) kit (Intergen Company,
Oxford, UK) according to the manufacturer’s instructions. To
define the sensitivity of the method and the semiquantitative
relationship between protein concentration and ladder band
intensity, different amounts of protein extract (from 0.1 to 2mg)
were used for each purified lymphocyte culture and for all assays.
The appropriate protein concentration to produce a linear
response was 1mg of the total protein. In all cases, reaction
products were amplified in the presence of a 36bp internal TRAP
assay standard (ITAS), and each extract was tested for RNAse
sensitivity, incubating samples with 20ng RNAse (Sigma) for
30min at 371C before extension/amplification reaction. Telomeric
repeat amplification protocol assay included a sample without cell
lysate as negative control and a positive control sample provided
by the kit. Telomere length was evaluated by Southern blot as
previously reported (Biroccio et al, 2002). Briefly, total DNA was
isolated using standard procedure. For each sample, 15mg of DNA
were digested with 40U of Hinf1 and electrophoresed on 0.8%
agarose gel. DNA was denatured, neutralised, transferred to a
nylon membrane (Hybond N, Amersham International, Buck-
inghamshire, UK) and cross-linked with ultraviolet light. The
membrane was hybridized with 50-end [g-
32P] deoxyadenosine
triphosphate-labelled telomeric oligonucleotide probe (TTAGGG)3
at 421C for 4h in a rapid hybridization buffer (QuikHyb
Hybridization Solution, Stratagene, La Jolla, USA). After washing,
the filters were autoradiographed (Hyperfilm-MP; Amersham)
with an intensifying screen at  801C for 24h. The autoradiographs
were scanned and the mean telomere length was calculated as
reported by Harley et al (1990).
Cell cycle analysis and detection of apoptosis
The percentage of cells in the different phases of cell cycle was
determined by evaluating DNA content. Treated and untreated
cells (2 10
6) were collected at 72h of culture, washed with PBS
and fixed with 2ml of 70% ethanol. After washing twice in PBS, the
cells were stained with a solution containing 50mgml
 1 propidium
iodide (PI) and 75kU/ml RNAse in PBS for 30min at room
temperature. A total of 20000 events per sample were acquired by
FACSCalibur (Becton-Dickinson) using a doublet discrimination
module (DDM). The percentages of cell cycle distribution and
subG1 apoptotic cells were calculated on linear PI histograms
using the mathematical software ModFit. Apoptotic cells were also
detected by using the APO-BRDUt kit (BioSource International,
Camarillo, California), a terminal deoxynucleotide transferase
(TdT)-mediated Br-dUTP nick-end labelling (TUNEL), according
to the manufacturer’s instruction. Briefly, 2 10
6 of treated and
untreated cells were collected at 72h of culture, washed with PBS
and fixed with 2ml of 70% ethanol. The fragmented DNA was
revealed incubating the samples with the labelling reaction mix
for 1h at 371C; the BrdU-labelled cells were then stained with a
fluorescein-labelled anti-BrdU antibody solution for 30min at
room temperature, in the dark. To determine DNA content, a PI/
RNAse solution was added to FITC-labelled cells and incubated for
30min at room temperature, in the dark.
Statistical analysis
Statistical evaluation of apoptosis and cell cycle data was
performed by Student’s t-test.
RESULTS
Telomerase activity and telomere length in AT
lymphocytes expressing TCL1
In order to study the correlation between chromosome end-to-end
fusions (tas) and telomere metabolism, we evaluated telomerase
activity and telomere length in PHA-stimulated lymphocytes
characterised by different tas frequency. The cells used were: AT
lymphocytes with TCL1 expression (AT94-1), which are charac-
terised by a high frequency of spontaneous tas (Table 1); Ataxia
telangiectasia lymphocytes without TCL1 expression (AT95-1 and
AT95-2) showing sporadic tas; and normal lymphocytes, with no
detectable tas. The telomerase activity was evaluated by a
semiquantitative TRAP assay. Figure 1 shows that the loss of the
ATM function alone determines a marked decrease in telomerase
activity (see AT95-1 and AT95-2), while the expression of TCL1,
characteristic of AT94-1 clonal lymphocytes, is able to restore
telomerase activity up to the level observed in normal lympho-
cytes. The internal telomerase assay standard (ITAS) was amplified
to the same extent in all cell cultures, excluding the presence of
Taq polymerase inhibitors in AT lymphocytes without TCL1
expression.
We then tried to determine whether the increase of telomerase
activity observed in AT cells expressing TCL1 was associated with
reduced telomere shortening. Terminal restriction fragments
(TRFs) were obtained by Southern blotting in the same cells
analysed by TRAP assay (Table 2). TRFs in AT lymphocytes
without TCL1 expression were shorter (mean value 13.1kb) than in
normal lymphocytes (mean value 15.6kb). AT94-1 lymphocytes
(expressing TCL1) showed a telomere length range superimposable
to that observed in AT lymphocytes not expressing TCL1, although
these two kinds of AT cells have different telomerase activity and
different tas frequency.
Ataxia telangiectasia lymphocytes expressing TCL1
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progression in AT lymphocytes expressing TCL1
In order to ascertain whether the differences in telomere
metabolism in cells that have lost the ATM function are due to
different rates of proliferation and/or apoptosis, we analysed these
two features comparing AT lymphocytes with and without TCL1
expression. A flow cytometric TUNEL assay, performed in a
biparametric analysis with DNA content (Figure 2A), was carried
out in four different samples of normal lymphocytes, in two AT
lymphocytes (AT95-1, AT95-2) and in AT94-1 lymphocytes. Each
sample was analysed at least three times. Figure 2B shows the mean
values of apoptotic cells (dark grey columns) together with the
mean percentages of cells in the different phases of cell cycle (G0/
G1, white columns; S-G2/M, grey columns). Ataxia telangiectasia
lymphocytes without TCL1 expression (see AT) were characterized
Table 1 Spontaneous telomeric associations (tas) in metaphases with
t(14;14) from AT94-1 lymphocytes
Date
No. cells
analysed
Metaphases
with tas
Metaphases with
subclonal
rearrangements
2001 52 tas(21;22)(p11;p11)  22,+mar1[2]
tas(18;21)(p11;p11) i (21)(q10)[5]
del(7)(p11) tas(18;13)(q23;q34)
tas(10;21)(p15;p11)
i (21)(q10),
tas(10;15)(p15;p11)
tas(5;9)(p15;q34)
tas(5;22)(p15;p11)
i (21)(q10),
tas(1;18)(p36;p11)
+5, 22, tas(11;21)(q25;q22) +6, i (21)(q10)
 18, i(18)(q10), tas (dert[14;14]
[q11;q32];7)(p11;q36)
t(5;13)(q12;q12),
tas(13;17)(p11;p13),
tas(9;18)(q34;p11)
2002 56 tas(4;21)(p16;p11)  22,+mar1 [2]
tas(5;6)(p15;p25) i (21)(q10) [3]
tas(21;21)(p11;q22) i (21)(q10),
tas(4;13)(p16;q34) inv(3)(p21q11)
+X, tas(12;18)(q24;p11)
tas(21;22)(p11;q13)
tas(2;18)(q37;p11)
tas(5;15)(p15;p11)
tas(4;21)(p16;q22)
The metaphases with the t(14;14) rearrangement represented 80 and 73% of total
AT94-1 lymphocytes, respectively, in 2001 and in 2002. Metaphases with sporadic
nonclonal rearrangements were also observed (data not shown). The cytogenetic
follow-up of AT94-1 from 1995 to 2000 has been previously reported (Petrinelli et al,
2001).
Table 2 Terminal restriction fragments calculated by Southern blot
analysis of normal, AT and TCL1 espressing AT lymphocytes hybridized
with the telomeric repeats (TTAGG)3
Cells
Telomere length (kbp)
Min Max
AT
+ TCL1
  12.270.2 19.070.2
AT
  TCL1
  10.670.2 15.670.1
AT
  TCL1
+ 10.570.2 15.770.1
The results are the mean values of three experiments.
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Figure 2 Evaluation of apoptosis and DNA content of different types of
lymphocytes. (A) Results of a representative TUNEL assay performed on
four samples of normal lymphocytes, two of AT lymphocytes (AT95-1 and
AT95-2) and one of TCL1 expressing AT lymphocytes (AT94-1). (B)
TUNEL-positive cell percentage (dark grey columns), cell percentage in the
G0/G1 phase (white columns) and in the S–G2/M phase (grey columns) of
cell cycle. Each experiment was performed at least three times. – RNAse
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Figure 1 TRAP assay to evaluate the effect of ATM status and TCL1
expression on telomerase activity in human PHA-stimulated lymphocytes.
From left to right: a negative control; a sample of normal lymphocytes; two
samples of AT lymphocytes (AT95-1, AT95-2); a sample of AT
lymphocytes expressing TCL1 (AT94-1); a positive control.
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programme (53.370.4) if compared with normal lymphocytes
(17.072.1) and showed a strong proliferative block in the G0/G1
phase. The expression of TCL1 in AT cells determined a decrease
of the apoptotic rate (32.975.3) and was able to restore a ‘normal
like’ cell cycle by driving the AT cells in the S phase. In fact, the
differences in the percentage of cells in G0/G1 and S–G2/M phases
between normal and AT94-1 lymphocytes were not significant
(P40.05).
We next evaluated the same parameters in the same cells after
DNA damage induction by VP16 treatment (Table 3). As expected,
in normal lymphocytes (AT
þ TCL1
 ) VP16 treatment induced a
significant (Po0.01) increase of the percentage of cells in SþG2/M
compartement and in apoptosis, while we observed no significant
(P40.05) change for both parameters in control AT lymphocytes
(AT
  TCL1
 ). On the contrary, in AT lymphocytes expressing TCL1
(AT
  TCL1
þ) VP16 treatment determined an increase of apoptosis
rate and of percentage of cells in the S–G2/M compartment
comparable to those observed in normal lymphocytes.
DISCUSSION
In this study, we demonstrated that AT94-1 T lymphocytes have
lost the general growth disadvantage caused by the lack of the
ATM function. The dramatic reduction of cells in the S and G2
phases of the cell cycle, characteristic of nonclonal AT lympho-
cytes, was not observed in AT94-1 lymphocytes since these cells
showed a cell cycle distribution similar to that observed in normal
cells. Furthermore, our results suggest that TCL1 expression is
correlated with a reduced apoptotic rate in the apoptotic-prone
ATM
  cells (Duchaud et al, 1996). The differences in cell
proliferation and survival were also evident in cells treated with
VP16, a topoisomerase II inhibitor that acts at premitotic phase
and induces apoptosis in mitogen-activated T lymphocytes
(Sinkule, 1984; Ferraro et al, 2000). Indeed, when damaged with
VP16, only ATM
  TCL1
þ lymphocytes were able to show an
increase, both in apoptosis rate and in percentage of cells in the S–
G2/M compartment, similar to that observed in VP16-treated
normal lymphocytes (ATM
þ TCL1
 ).
We also showed that AT94-1 cells exhibited telomere shortening,
increased telomerase activity and chromosomal instability, especially
telomeric end-to-end fusions (tas). The coexistence of telomere
instability and telomerase activation in AT94-1 cells can be explained
by taking into account that telomerase activity does not necessarily
result in telomere elongation, in agreement with previous studies
(Metcalfe et al,1 9 9 6 ) .I n d e e d ,t e l o m e r a s em i g h th a v ead u a lf u n c t i o n
for telomeres, protection and elongation, and could therefore
promote cell survival and growth, independently of net telomere
elongation (Zhu et al, 1999; Blasco, 2002). We also observed that
endogenous expression of telomerase in AT94-1 cells is unable to
correct the cytogenetic phenotype of telomere instability (i.e. tas). In
agreement with this, Wood et al (2001) showed that the ectopical
expression of the human telomerase gene hTERT in AT fibroblasts
does not correct the telomere end-association defect, despite
maintaining/extending telomere length. Thus, tas frequency could
be dependent on ATM loss, but is telomerase independent. In fact, as
suggested by Pandita and Dhar (2000), ATM could be involved in
telomere-mediated function through telomere–nuclear matrix inter-
action. Therefore, AT94-1 lymphocytes regain telomerase activity
despite high frequency of tas, show low spontaneous apoptosis rate
and restore cell cycle progression. It is then TCL1 expression that
confers these advantages to ATM
  cells. Even though we cannot
exclude that other undetected genetic alterations might be present in
the clonal cells, TCL1 seems to play an important role in these
features. This idea is consistent with the observation that TCL1 is
uniquely expressed in AT94-1 lymphocytes and not in other AT or
normal T lymphocytes (Narducci et al, 1995, 2000) and that it has a
proliferative and antiapoptotic role as demonstrated by recent
biochemical findings and studies in animal models. More specifically,
biochemical evidence demonstrates that Tcl1 acts in vivo as a
coactivator of the Akt protein, enhancing its kinase activity and
mediating its nuclear translocation (Pekarsky et al, 2000; Kunstle et al,
2002). Akt, in turn, has a central role in the regulation of several
signalling pathways controlling cell survival and proliferation in T
cells. Indeed, activated Akt enhances human telomerase activity
through phosphorylation of the hTERT subunit (Kang et al, 1999),
inhibits the proapoptotic factor Bad (Nicholson and Anderson, 2002)
and, in T lymphocytes, has a key role in G1–S phase progression
through the regulation of pRB (retinoblastoma protein) phosphor-
ylation (Brennan et al, 1997). The same pathway Akt/pRB/E2F is
required also to protect activated peripheral T cells from bcl-2-
independent apoptosis (Lauder et al, 2001). The overexpression of
this gene in T or B lymphocytes of transgenic mice induces,
respectively, a T-PLL, B-CLL or mature B-cell lymphoma (Virgilio
et al, 1998; Bichi et al, 2002; Hoyer et al, 2002). Interestingly, Fears
et al (2002) reported that one cell line, derived from a relapse in a
child with acute lymphatic leukaemia (ALL), showed TCL1 over-
expression and a much higher rate of proliferation when compared to
a previously established cell line from the same patient. The increase
in TCL1 expression correlates with disease progression and more
aggressive phenotype in this child.
In conclusion, clonal T cells carrying t(14;14) chromosomal
translocation and expressing TCL1 seem to be able to restore some
of the biological properties that are lost in AT cells; this might
explain why these T cells have greater expansion and survival rate
and are most often observed in AT patients. This assumes even
more relevance if we consider that a similar situation of ATM
biallelic loss and TCL1 overexpression, other than in AT patients,
exists also in several sporadic human cancer types, such as T-PLL,
B-CLL and mantle cell lymphoma, suggesting that these two genes
cooperate in the development of certain lymphoid tumours.
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